EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, PSNL: Personalis Inc

17 Apr 26 15:59
LAST:

6.720

CHANGE:
 0.07		OPEN:
6.690		HIGH:
7.040		ASK:
0.000		VOLUME:
939.0K
CHG(%):
1.05		PREV:
6.660		LOW:
6.690		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
17 Apr 266.9607.0406.7206.7301.4M
16 Apr 266.6606.7906.4256.660879.8K
15 Apr 266.7506.9006.5006.6301.49M
14 Apr 266.4806.7906.4706.680999.3K
13 Apr 265.9806.5575.9006.3101.33M
10 Apr 266.1506.2105.8806.0201.43M
09 Apr 266.2956.2955.8106.0901.66M
08 Apr 266.7106.8796.2706.3301.73M
07 Apr 266.4406.4406.0006.1701.7M
06 Apr 266.6106.7506.5056.580701.8K

PROFILE

Name:Personalis Inc
About:Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company has strategic collaboration with Tempus AI, Inc. to bring ultra-sensitive cancer recurrence testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.
Sector:Healthcare
Address:6600 Dumbarton Circle, Fremont, CA, United States, 94555
Website:https://www.personalis.com
CUSIP:71535D106
CIK:0001527753
ISIN:US71535D1063
FIGI:BBG0027NWBR8
LEI:549300EZ2NYFK7H0US48

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-6.57 
Forward P/E:-7.06 
PEG Ratio:1.58 
Price to Sales:10.64 
Price to Book:2.59 
Profit Margin:-1.14 
Operating Margin:-1.27 
Return on Assets:-0.20 
Return on Equity:-0.60 
EPS Ratio:-0.91 
Revenue:80.32M 
Shares:104.63M 
Market Cap:703.13M 

TECHNICAL INDICATORS

MA5:6.601.8%
MA10:6.424.7%
MA20:6.700.3%
MA50:7.5612.5%
MA100:8.3924.9%
MA200:7.5512.3%
STO9:69.61
STO14:69.61
RSI14:59.15
MTM14:0.49
ROC14:0.08 
ATR:0.47 
Week High:7.044.8%
Week Low:5.8814.3%
Month High:8.2322.5%
Month Low:5.8112.3%
Year High:11.5071.1%
Year Low:3.09117.5%
Volatility:31.96